InsidersTradesSigma
Track the Iovance Biotherapeutics, INC. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Health Care sector, Iovance Biotherapeutics, INC. has logged 108 reports. Market capitalisation: €2.3bn. The latest transaction was disclosed on 12 August 2026 (Levée d'options). Among the most active insiders: BILINSKY IGOR. The full history is openly available.
108
Insider Decl.
n/a
Thresholds
€135m
19 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Iovance Biotherapeutics, INC. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
35Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,027 of 29,053 companies
22.3
score / 100
Value16
Quality28
FCF yld-9.3%
Earn yld-11%
EV/EBITDA·
ROE-40%
Gross mgn34%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 August 2026
Declarations108 total
10,001 shares0Common StockSEC:0001104659-26-095040:0
2,436 shares@ US$6.40Common StockSEC:0001104659-26-095040:1
49,995 shares0Common StockSEC:0001104659-26-093482:0
21,238 shares@ US$6.210.0060% mcap100.0% of flowCommon StockSEC:0001104659-26-093482:1
7,813 shares0Common StockSEC:0001104659-26-071891:0
3,976 shares@ US$4.230.0008% mcap39.3% of flowCommon StockSEC:0001104659-26-071891:1
7,813 shares0Common StockSEC:0001104659-26-071897:0
3,976 shares@ US$4.230.0008% mcap100.0% of flowCommon StockSEC:0001104659-26-071897:1
8,790 shares0Common StockSEC:0001104659-26-070149:0
4,473 shares@ US$3.9668.2% of flowCommon StockSEC:0001104659-26-070149:1
62,493 shares0Common StockSEC:0001104659-26-024765:0
31,246 shares0Common StockSEC:0001104659-26-024762:0
39,059 shares0Common StockSEC:0001104659-26-024760:0
31,246 shares0Common StockSEC:0001104659-26-024759:0
52,087 shares0Common StockSEC:0001104659-26-023539:0
12,307 shares0Common StockSEC:0001104659-26-023538:0
5,470 shares0Common StockSEC:0001104659-26-023537:0
12,697 shares0Common StockSEC:0001104659-26-023535:0
120,000 shares0Common StockSEC:0001104659-26-020613:0
39,996 shares0Common StockSEC:0001104659-26-014400:0
8,789 shares0Common StockSEC:0001104659-25-118170:0
8,789 shares0Common StockSEC:0001104659-25-118169:0
41,669 shares0Common StockSEC:0001104659-25-118168:0
5,469 shares0Common StockSEC:0001104659-25-118167:0
52,086 shares0Common StockSEC:0001104659-25-087549:0
25 of 108 declarations
About Iovance Biotherapeutics, INC.
Iovance Biotherapeutics, INC. is a biopharmaceutical company focused on developing cell therapies for cancer treatment. It specializes in using modified T cells to target and destroy tumor cells.